Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
AML MRD Flow Panel
- Flow Cytometry
MRD assessment has the potential to improve outcomes for patients with acute myeloid leukemia (AML). Available as Global test only. Markers are CD7, CD11b, CD13, CD14, CD15, CD16, CD19, CD2, CD33, CD34, CD38, CD4, CD45, CD56, CD64, CD65, CD87, CD117, CD371, HLA-DR (20 markers). This panel can detect MRD at the 0.01% level.
Specimen Requirements
Bone marrow aspirate: 2-3 mL, first pull. EDTA preferred. Sodium heparin tube acceptable.
Lithium heparin or ACD (pale yellow/no gel separator) not acceptable. Please provide recent CBC report.
NY Clients: Please provide Date and Time of Collection.
Storage and Transportation
Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Note: New York State samples must be received within 48 hours from collection per NYS requirements. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
CPT Code(s)*
88184x1, 88185x19. Add 88189x1 for Global
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Biomarkers
Flow Cytometry
| Markers | |||||
|---|---|---|---|---|---|
| CD4 | CD87 | CD371 | CD117 | CD19 | CD11b |
| CD34 | CD13 | CD14 | CD16 | CD33 | CD64 |
| HLA-DR | CD38 | CD2 | CD56 | CD7 | CD15 |
| CD65 | CD45 | ||||
Last Updated: January 13, 2026